NASDAQ: EVAXEvaxion A Stock
$3.10+0.15 (+5.08%)
Updated Aug 21, 2025
EVAX Price
$3.10
Fair Value Price
N/A
Market Cap
$19.59M
52 Week Low
$1.20
52 Week High
$17.75
P/E
-0.48x
P/B
3.15x
P/S
1.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.18M
Earnings
-$11.97M
Gross Margin
100%
Operating Margin
-323.11%
Profit Margin
-377%
Debt to Equity
2.61
Operating Cash Flow
-$12M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EVAX Overview
Evaxion Biotech A/S develops novel immunotherapies to treat various cancers, bacterial diseases, and viral infections suing proprietary AI platforms (PIONEER, EDEN, and RAVENTM). The company's drug candidates include EVX-01, EVX-02, and EVX-03. Evaxion Biotech A/S has collaboration agreements with the National Center at Herlev Hospital, the Department of Health Technology at Danish Technical University, and other institutions. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EVAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EVAX
Ranked#66 of 482
Ranked#66 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.66 | A | |
| $41.99 | A | |
| $12.08 | A |
Be the first to know about important EVAX news, forecast changes, insider trades & much more!
EVAX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EVAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EVAX is good value based on its book value relative to its share price (3.15x), compared to the US Biotechnology industry average (4.56x)
P/B vs Industry Valuation
EVAX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EVAX due diligence checks available for Premium users.
Valuation
EVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
-113.73x
Market
34.76x
EVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.15x
Industry
4.56x
EVAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EVAX's financial health
Profit margin
Revenue
$37.0k
Net Income
-$4.8M
Profit Margin
-13,056.8%
EVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EVAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.4M
Liabilities
$16.2M
Debt to equity
2.61
EVAX's short-term assets ($18.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EVAX's short-term assets ($18.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EVAX vs Biotech Stocks
Evaxion A Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.